Shots:
- Chai Discovery has raised $400M in a Series C round to develop AI models that predict & engineer molecular interactions to speed preclinical drug discovery
- The Series C round, valuing Chai at $3.8B, was led by Index Ventures with participation from Kleiner Perkins, Sequoia Capital, Dimension, and several new and existing investors
- The company’s latest model, Chai-3 is improving target success rates & binding affinity, while Chai-2 was the first zero-shot generative platform to achieve double-digit experimental success rates for fully de novo antibody design
Ref: Businesswire | Image: Chai Discovery | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
